Compass Therapeutics Inc. (CMPX) News
Filter CMPX News Items
CMPX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest CMPX News From Around the Web
Below are the latest news stories about COMPASS THERAPEUTICS INC that investors may wish to consider to help them evaluate CMPX as an investment opportunity.
Compass Therapeutics Inc (CMPX) Reports Q3 2023 Financial Results and Corporate DevelopmentsStrategic Clinical Advancements and Leadership Transition Announced Amidst Financial Review |
Compass Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateOpened 29 clinical sites and continue to enroll patients in COMPANION-002, a U.S. Phase 2/3 study of CTX-009 in combination with Paclitaxel in patients with advanced biliary tract cancers (BTC); top line data from this study is expected in the second half of 2024Continue to enroll and follow patients in COMPANION-003, a U.S. Phase 2 study of CTX-009 (DLL4 /VEGF-A bispecific antibody) in patients with advanced colorectal cancer (CRC); initial data from this study is expected before the end of the |
Compass Therapeutics to Participate in Upcoming Investor EventsBOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of November 2023. Details are as follows: Stifel Healthcare Conference Location: New York, NYDate: Tuesday, November 14, 2023 Time: 9:45am ESTWebcast Link: https://wsw.c |
3 Healthcare Stocks To Make You The Millionaire Next Door: October EditionThese are the healthcare stocks to buy as they represent companies investing in research and development for growth and value creation. |
Compass Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateContinuing to enroll patients in a U.S. Phase 2 study of CTX-009 (DLL4 /VEGF-A bispecific antibody) in patients with advanced colorectal cancer (CRC); initial data from this study is expected in the second half of 2023Opened 20 clinical sites and continues to enroll patients in a U.S. Phase 2 study of CTX-009 in patients with advanced biliary tract cancers (BTC); top line data from this study is now expected in the second half of 2024Completed enrollment of the dose-escalation portion of the Pha |
Compass Therapeutics to be Added to the Russell 2000® and Russell 3000® IndexesBOSTON, June 22, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that it will be added to the Russell 2000® and Russell 3000® Indexes as part of the Russell indexes annual reconstitution, effective after the US market opens on June 26, 2023. Membership in the US all-cap Russell 3000® Index, which remains in place for |
Compass Therapeutics Reports First Quarter Financial Results and Provides Corporate UpdateInitiated patient enrollment in a U.S. Phase 2/3 study of CTX-009 (DLL4 /VEGF-A bispecific antibody) in patients with advanced biliary tract cancers (BTC). Top line data is expected in the first half of 2024Continue to enroll in a U.S. Phase 2 study of CTX-009 in patients with advanced colorectal cancer (CRC). Initial data expected in the third quarter of 2023Presented results of a Phase 2 study of CTX-009 in combination with paclitaxel in patients with BTC at the 2023 ASCO GI Cancers SymposiumE |
Compass Therapeutics to Participate in the H.C. Wainwright BioConnect Investor Conference at NASDAQBOSTON, April 26, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the H.C. Wainwright BioConnect Investor Conference in New York City on Tuesday, May 2, 2023. Fireside Chat details:Date: Tuesday, May 2Time: 10 AM ETWebcast: https://journey.ct.events/view/059d01ae-0fdd-4419-8329-ac |
Compass Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology DaysBOSTON, April 19, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the Stifel 2023 Virtual Targeted Oncology Days, which is taking place on April 25 – 26, 2023. Fireside Chat details: Date: Wednesday, April 26Time: 11 AM ET Webcast: https://wsw.com/webcast/stifel78/cmpx/2115088 Vir |
Compass Therapeutics to Participate in the Cantor Fitzgerald Future of Oncology SymposiumBOSTON, March 28, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the Cantor Fitzgerald Future of Oncology Symposium, which is taking place virtually on April 3 – 5, 2023. Presentation details: Date: Tuesday, April 4 Time: 8:15 AM ET About Compass TherapeuticsCompass Therapeutics, |